USD10
DCTH Shares
About Delcath SystemsDelcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
USD10
DCTH Shares
About Delcath SystemsDelcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$311.67M
OPEN PRICE
$9.12
LOW (1Y)
$8.12
HIGH (1Y)
$18.23
LOW (24H)
$8.87
HIGH (24H)
$9.20
VOLUME (24H)
$282.53K
39.15%
Price history
Time | Price | Change |
|---|---|---|
Today | $9.12 | |
1 Day | $9.20 | |
1 Week | $9.00 | |
1 Month | $8.88 | |
1 Year | $12.73 |